Historical Valuation
VolitionRX Ltd (VNRX) is now in the Fair zone, suggesting that its current forward PS ratio of 9.25 is considered Fairly compared with the five-year average of -4.20. The fair price of VolitionRX Ltd (VNRX) is between 0.29 to 0.45 according to relative valuation methord.
Relative Value
Fair Zone
0.29-0.45
Current Price：0.33
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
VolitionRX Ltd (VNRX) has a current Price-to-Book (P/B) ratio of -0.86. Compared to its 3-year average P/B ratio of -10.37 , the current P/B ratio is approximately -91.67% higher. Relative to its 5-year average P/B ratio of -0.89, the current P/B ratio is about -2.90% higher. VolitionRX Ltd (VNRX) has a Forward Free Cash Flow (FCF) yield of approximately -58.98%. Compared to its 3-year average FCF yield of -32.94%, the current FCF yield is approximately 79.05% lower. Relative to its 5-year average FCF yield of -24.32% , the current FCF yield is about 142.52% lower.
P/B
Median3y
-10.37
Median5y
-0.89
FCF Yield
Median3y
-32.94
Median5y
-24.32
Competitors Valuation Multiple
AI Analysis for VNRX
The average P/S ratio for VNRX competitors is 1.99, providing a benchmark for relative valuation. VolitionRX Ltd Corp (VNRX.A) exhibits a P/S ratio of 9.25, which is 364.6% above the industry average. Given its robust revenue growth of 32.19%, this premium appears sustainable.
Performance Decomposition
AI Analysis for VNRX
1Y
3Y
5Y
Market capitalization of VNRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VNRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VNRX currently overvalued or undervalued?
VolitionRX Ltd (VNRX) is now in the Fair zone, suggesting that its current forward PS ratio of 9.25 is considered Fairly compared with the five-year average of -4.20. The fair price of VolitionRX Ltd (VNRX) is between 0.29 to 0.45 according to relative valuation methord.
What is VolitionRX Ltd (VNRX) fair value?
VNRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of VolitionRX Ltd (VNRX) is between 0.29 to 0.45 according to relative valuation methord.
How does VNRX's valuation metrics compare to the industry average?
The average P/S ratio for VNRX's competitors is 1.99, providing a benchmark for relative valuation. VolitionRX Ltd Corp (VNRX) exhibits a P/S ratio of 9.25, which is 364.60% above the industry average. Given its robust revenue growth of 32.19%, this premium appears sustainable.
What is the current P/B ratio for VolitionRX Ltd (VNRX) as of Jan 11 2026?
As of Jan 11 2026, VolitionRX Ltd (VNRX) has a P/B ratio of -0.86. This indicates that the market values VNRX at -0.86 times its book value.
What is the current FCF Yield for VolitionRX Ltd (VNRX) as of Jan 11 2026?
As of Jan 11 2026, VolitionRX Ltd (VNRX) has a FCF Yield of -58.98%. This means that for every dollar of VolitionRX Ltd’s market capitalization, the company generates -58.98 cents in free cash flow.
What is the current Forward P/E ratio for VolitionRX Ltd (VNRX) as of Jan 11 2026?
As of Jan 11 2026, VolitionRX Ltd (VNRX) has a Forward P/E ratio of -1.66. This means the market is willing to pay $-1.66 for every dollar of VolitionRX Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for VolitionRX Ltd (VNRX) as of Jan 11 2026?
As of Jan 11 2026, VolitionRX Ltd (VNRX) has a Forward P/S ratio of 9.25. This means the market is valuing VNRX at $9.25 for every dollar of expected revenue over the next 12 months.